Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 25, 2009

Lonza to Manufacture Micromet’s Blinatumomab BiTE Antibody

  • Lonza is to carry out process development and manufacture of Micromet’s clinical-stage CD19-targeting BiTE antibody, blinatumomab (MT103). Under terms of the deal Lonza will manufacture blinatumomab for clinical trials, develop a commercial-scale process, and supply commercial quantities of the drug if requested.

    Blinatumomab is a lymphoma-directed, recombinant bispecific single-chain antibody generated using Micromet's BiTE® antibody technology. The candidate is currently undergoing Phase II trials in acute lymphoblastic leukemia, and a Phase I trial in non-Hodgkin lymphoma.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »